Beiersdorf (BEI) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
27 Apr, 2026Opening remarks and agenda
AGM held virtually with increased shareholder participation and full digital rights to speak, submit motions, and vote via the AGM system.
Next in-person AGM planned for 2028, coinciding with Supervisory Board elections.
Agenda, proposed resolutions, and supporting documents published in advance; all legal requirements for convening met.
Financial performance review
2025 turnover reached EUR 9.9 billion, with 2.4% organic growth; earnings and profitability improved year-on-year.
Derma segment grew 11.7% organically, reaching EUR 1.5 billion; healthcare segment grew 9.3% to EUR 300 million.
NIVEA turnover grew 0.9% to EUR 5.5 billion, below expectations; La Prairie turnover fell 4.5% to EUR 478 million.
tesa segment grew 1.8% to EUR 1.7 billion, driven by industrial and e-commerce business.
Dividend of EUR 1 per share proposed; share buyback program up to EUR 750 million planned over next two years.
Forecast for 2026: flat to slightly positive organic sales growth, EBIT margin slightly below previous year.
Board and executive committee updates
Supervisory Board fulfilled duties per law and governance code; meetings focused on financials, strategy, and sustainability.
Executive Board remuneration system revised and approved, emphasizing long-term value creation and transparency.
No major changes to Executive Board except Mr. Rasquinet's departure in July 2025.
Latest events from Beiersdorf
- Q1 2026 organic sales fell 4.6%, but Derma growth and NIVEA rebalancing support optimism.BEI
Q1 202626 Apr 2026 - Solid 2025 growth driven by Derma, with flat outlook and margin pressure expected in 2026.BEI
Q4 202525 Apr 2026 - 7.1% organic sales growth, margin expansion, and guidance reaffirmed despite market headwinds.BEI
Q2 20242 Feb 2026 - Strong 6.5% organic sales growth led by NIVEA and Derma; guidance for 6–8% reaffirmed.BEI
Q3 202419 Jan 2026 - Record sales, margin gains, and innovation drive strong 2024 results; 2025 outlook remains positive.BEI
Q4 20247 Jan 2026 - Q1 2025 organic sales up 3.6%, with Derma and tesa outperformance; guidance reaffirmed.BEI
Q1 202527 Dec 2025 - Organic sales rose 2.0% to €7.5B, led by Derma, as guidance was trimmed amid market slowdown.BEI
Q3 20253 Dec 2025 - Organic sales up 2.1% in H1 2025, with stable margins and strong Derma growth.BEI
Q2 202523 Nov 2025 - Accelerated growth, innovation, and sustainability drive Beiersdorf’s leadership in global skin care.BEI
CMD 2024 Presentation13 Jun 2025